(Q36817045)

16 August 2017

1 reference

title

Gene therapy applications for the treatment of neuropathic pain (English)

1 reference

16 August 2017

0 references

0 references

James R Goss

1

1 reference

16 August 2017

William F Goins

series ordinal

2

1 reference

16 August 2017

Joseph C Glorioso

series ordinal

3

1 reference

16 August 2017

language of work or name

1 reference

1 May 2007

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

16 August 2017

1 reference

16 August 2017

7

1 reference

16 August 2017

487-506

1 reference

16 August 2017

5

1 reference

An overview of neuropathic pain: syndromes, symptoms, signs, and several mechanisms.

16 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Clinical characteristics and economic costs of patients with painful neuropathic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

The induction of pain: an integrative review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Endogenous Pain Control Systems: Brainstem Spinal Pathways and Endorphin Circuitry

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Molecular mechanisms of nociception

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Neuronal plasticity and signal transduction in nociceptive neurons: implications for the initiation and maintenance of pathological pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Pain mechanisms and management: a central perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Bradykinin and nerve growth factor release the capsaicin receptor from PtdIns(4,5)P2-mediated inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Pathobiology of neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Silent afferents: a separate class of primary afferents?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Evidence for spinal N-methyl-D-aspartate receptor involvement in prolonged chemical nociception in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

The role of neuroinflammation and neuroimmune activation in persistent pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Immune activation: the role of pro-inflammatory cytokines in inflammation, illness responses and pathological pain states

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Glial activation: a driving force for pathological pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Bradykinin initiates cytokine-mediated inflammatory hyperalgesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Dynamic regulation of proinflammatory cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Intrathecally administered endotoxin or cytokines produce allodynia, hyperalgesia and changes in spinal cord neuronal responses to nociceptive stimuli in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Anti-inflammatory interleukin-10 therapy in CCI neuropathy decreases thermal hyperalgesia, macrophage recruitment, and endoneurial TNF-alpha expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Cytokine-mediated inflammatory hyperalgesia limited by interleukin-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Antinociceptive effects of interleukin-4, -10, and -13 on the writhing response in mice and zymosan-induced knee joint incapacitation in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Staining of glial fibrillary acidic protein (GFAP) in lumbar spinal cord increases following a sciatic nerve constriction injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Microglial reactions after subcutaneous formalin injection into the rat hind paw.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Acute peripheral inflammation induces moderate glial activation and spinal IL-1beta expression that correlates with pain behavior in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

The pain of being sick: implications of immune-to-brain communication for understanding pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

New treatments for neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Challenges in the development of novel treatment strategies for neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

The number needed to treat: a clinically useful measure of treatment effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Lidocaine patch: double-blind controlled study of a new treatment method for post-herpetic neuralgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: results of an enriched enrollment study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Lidocaine patch 5% reduces pain intensity and interference with quality of life in patients with postherpetic neuralgia: an effectiveness trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

The lidocaine patch 5% effectively treats all neuropathic pain qualities: results of a randomized, double-blind, vehicle-controlled, 3-week efficacy study with use of the neuropathic pain scale.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Topical lidocaine patch relieves a variety of neuropathic pain conditions: an open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Efficacy of lidocaine patch 5% in the treatment of focal peripheral neuropathic pain syndromes: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Systematic review of topical capsaicin for the treatment of chronic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Analgesic therapy in postherpetic neuralgia: a quantitative systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Wind-up and the NMDA receptor complex from a clinical perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Structure, function and pharmacology of voltage-gated sodium channels

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Pharmacotherapy of trigeminal neuralgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Use of anticonvulsants for treatment of neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Anticonvulsants for neuropathic pain syndromes: mechanisms of action and place in therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Sodium valproate for painful diabetic neuropathy: a randomized double-blind placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Efficacy of oxcarbazepine in the treatment of painful diabetic neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Rationale and Evidence for the Use of Oxcarbazepine in Neuropathic Pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Utilization of zonisamide in patients with chronic pain or epilepsy refractory to other treatments: a retrospective, open label, uncontrolled study in a VA hospital

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Gabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Gabapentin for the Treatment of Postherpetic Neuralgia: A Randomized Controlled Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Antidepressants in the treatment of neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Duloxetine vs. placebo in patients with painful diabetic neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Double-blind, randomized trial of bupropion SR for the treatment of neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Are opioids effective in relieving neuropathic pain?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Both intravenous lidocaine and morphine reduce the pain of postherpetic neuralgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Morphine responsiveness of chronic pain: double-blind randomised crossover study with patient-controlled analgesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Controlled-release oxycodone for pain in diabetic neuropathy: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Tramadol in post-herpetic neuralgia: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Tramadol relieves pain and allodynia in polyneuropathy: a randomised, double-blind, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Gene therapy for the management of pain: Part I: Methods and strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Gene therapy for the management of pain: part II: molecular targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Adrenal medullary tissue transplants in the rat spinal cord reduce pain sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Analgesia induced by isolated bovine chromaffin cells implanted in rat spinal cord

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Alleviation of neuropathic pain symptoms by xenogeneic chromaffin cell grafts in the spinal subarachnoid space.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Adrenal medullary implants in the rat spinal cord reduce nociception in a chronic pain model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Grafts of immortalized chromaffin cells bio-engineered to improve met-enkephalin release also reduce formalin-evoked c-fos expression in rat spinal cord

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Attempted gene therapy for intractable pain: dexamethasone-mediated exogenous control of beta-endorphin secretion in genetically modified cells and intrathecal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Synthetic DNA delivery systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Electroporation-mediated pain-killer gene therapy for mononeuropathic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Regulated, electroporation-mediated delivery of pro-opiomelanocortin gene suppresses chronic constriction injury-induced neuropathic pain in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Interleukin-2 gene therapy of chronic neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Gene Therapy for Bladder Pain With Gene Gun Particle Encoding Pro-Opiomelanocortin cDNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Gene gun particle encoding preproenkephalin cDNA produces analgesia against capsaicin-induced bladder pain in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

An antisense oligonucleotide primer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Knock down of spinal NMDA receptors reduces NMDA and formalin evoked behaviors in rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Antisense knockdown of spinal-mGluR1 reduces the sustained phase of formalin-induced nociceptive responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Antinociceptive effects after intrathecal administration of phosphodiester-, 2'-O-allyl-, and C-5-propyne-modified antisense oligodeoxynucleotides targeting the NMDAR1 subunit in mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Gene knockdown with intrathecal siRNA of NMDA receptor NR2B subunit reduces formalin-induced nociception in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

siRNA relieves chronic neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Intrathecal injection of cAMP response element binding protein (CREB) antisense oligonucleotide attenuates tactile allodynia caused by partial sciatic nerve ligation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Molecular and cellular barriers limiting the effectiveness of antisense oligonucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Viral vectors for gene delivery to the nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Viruses as gene delivery vectors: application to gene function, target validation, and assay development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Lentiviral vectors for use in the central nervous system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Reversal of neurochemical changes and pain-related behavior in a model of neuropathic pain using modified lentiviral vectors expressing GDNF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

A paracrine paradigm for in vivo gene therapy in the central nervous system: treatment of chronic pain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Controlling pathological pain by adenovirally driven spinal production of the anti-inflammatory cytokine, interleukin-10.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Adenovirus-mediated interleukin-2 gene therapy of nociception

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Evaluation of toxicity from high-dose systemic administration of recombinant adenovirus vector in vector-naive and pre-immunized mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Recombinant adeno-associated viral vectors in the nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Recombinant adeno-associated viral vectors as therapeutic agents to treat neurological disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Amelioration of chronic neuropathic pain after partial nerve injury by adeno-associated viral (AAV) vector-mediated over-expression of BDNF in the rat spinal cord

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Controlling neuropathic pain by adeno-associated virus driven production of the anti-inflammatory cytokine, interleukin-10

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Adeno-associated viral transfer of opioid receptor gene to primary sensory neurons: a strategy to increase opioid antinociception

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Remote nerve injection of mu opioid receptor adeno-associated viral vector increases antinociception of intrathecal morphine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Immune responses to adeno-associated virus vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Physical state of the latent herpes simplex virus genome in a mouse model system: evidence suggesting an episomal state

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Replication-defective herpes simplex virus vectors for gene transfer in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Deletion of multiple immediate-early genes from herpes simplex virus reduces cytotoxicity and permits long-term gene expression in neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Long-term neuroprotection achieved with latency-associated promoter-driven herpes simplex virus gene transfer to the peripheral nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Met-enkephalin is preferentially transported into the peripheral processes of primary afferent fibres in both control and HSV1-driven proenkephalin A overexpressing rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Antinociceptive effect of a genomic herpes simplex virus-based vector expressing human proenkephalin in rat dorsal root ganglion

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

HSV-mediated gene transfer of the glial cell-derived neurotrophic factor provides an antiallodynic effect on neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Transgene-mediated enkephalin release enhances the effect of morphine and evades tolerance to produce a sustained antiallodynic effect in neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Gene transfer of glutamic acid decarboxylase reduces neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

HSV-mediated expression of interleukin-4 in dorsal root ganglion neurons reduces neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Peripherally delivered glutamic acid decarboxylase gene therapy for spinal cord injury pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Antihyperalgesic effects of infection with a preproenkephalin-encoding herpes virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Reversal of ongoing thermal hyperalgesia in mice by a recombinant herpesvirus that encodes human preproenkephalin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Recombinant herpes vector-mediated analgesia in a primate model of hyperalgesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Direct adenovirus-mediated gene transfer of interleukin 1 and tumor necrosis factor alpha soluble receptors to rabbit knees with experimental arthritis has local and distal anti-arthritic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Changes in nociceptive and anxiolytic responses following herpes virus-mediated preproenkephalin overexpression in rat amygdala are naloxone-reversible and transient

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

IL-4 gene therapy for collagen arthritis suppresses synovial IL-17 and osteoprotegerin ligand and prevents bone erosion

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.487

Anticonvulsant drugs for acute and chronic pain

21 January 2018

1 reference

30 December 2023

https://opencitations.net/index/api/v1/citations/10.1002/14651858.CD001133.PUB2

Gabapentin for acute and chronic pain

1 reference

30 December 2023

https://opencitations.net/index/api/v1/citations/10.1002/14651858.CD005452

Identifiers

DOI

10.1586/14737175.7.5.487

1 reference

16 August 2017

1 reference